Sun Pharma's UNLOXCYT Receives NCCN Category 2A Recommendation for Advanced Skin Cancer
Sun Pharmaceutical Industries Ltd 路 Press Release 路 20 Oct 2026, 11:03 pm
Sun Pharma's UNLOXCYT Receives NCCN Category 2A Recommendation for Advanced Skin Cancer Sun Pharma announced on 20th Oct'26 that UNLOXCYT (cosibelimab-ipdl) has received an NCCN Category 2A recommendation for locally advanced cutaneous squamous cell carcinoma (laCSCC) in patients ineligible for curative surgery or radiation, complementing its existing '25 mCSCC designation. Pivotal trial data demonstrated a 55% objective response rate, 26% complete response rate, and under 1% high-grade immune-mediated adverse reactions, with median duration of response unreached at 24.1 months follow-up. This updated guideline designation is expected to strengthen institutional formulary adoption, payer coverage, and upfront patient access across the US.
Original exchange filing (PDF)
More announcements from Sun Pharmaceutical Industries Ltd
- Intimation of Schedule of Analyst/Institutional Investor Meeting 路 05 Nov 2026
- Q2FY27 Earnings Call Transcript 路 05 Nov 2026
- Clarification regarding news report relating to the Company''s Assam facility 路 03 Nov 2026
- The Exchange has sought clarification from Sun Pharmaceutical Industries Ltd on November 2, 2026, with reference to news appeared in https://www.thehindu.com/ dated October 30, 2026 quoting .... 路 02 Nov 2026
- Completion and results of postal ballot dated 01 October 2026 路 01 Nov 2026
- Q2FY27- Investor Call Audio Recording 路 31 Oct 2026
- Board Meeting Outcome - Conclusion 路 30 Oct 2026
- Unaudited Financial Results for the quarter and half year ended 30 September 2026 路 30 Oct 2026
